Relevant bibliographies by topics / Broadly neutralizing antibodies (bNAbs)

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Broadly neutralizing antibodies (bNAbs)'

Author: Grafiati
Published: 27 July 2024
Last updated: 31 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Broadly neutralizing antibodies (bNAbs).'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Broadly neutralizing antibodies (bNAbs)"

1

Karuna, Shelly T., and Lawrence Corey. "Broadly Neutralizing Antibodies for HIV Prevention." Annual Review of Medicine 71, no. 1 (2020): 329–46. http://dx.doi.org/10.1146/annurev-med-110118-045506.

Full text
Abstract:
In the last decade, over a dozen potent broadly neutralizing antibodies (bnAbs) to several HIV envelope protein epitopes have been identified, and their in vitro neutralization profiles have been defined. Many have demonstrated prevention efficacy in preclinical trials and favorable safety and pharmacokinetic profiles in early human clinical trials. The first human prevention efficacy trials using 10 sequential, every-two-month administrations of a single anti-HIV bnAb are anticipated to conclude in 2020. Combinations of complementary bnAbs and multi-specific bnAbs exhibit improved breadth and
APA, Harvard, Vancouver, ISO, and other styles
2

Yang, Guang, Mengfei Liu, Kevin Wiehe, et al. "HIV broadly neutralizing antibodies and immunological tolerance (VAC7P.988)." Journal of Immunology 192, no. 1_Supplement (2014): 141.33. http://dx.doi.org/10.4049/jimmunol.192.supp.141.33.

Full text
Abstract:
Abstract It is generally thought that many human antibodies (Ab) that neutralize multiple clades of HIV-1 (bnAbs) are self-reactive. We previously identified kynureninase as the primary self-antigen recognized by 2F5, suggesting that generation of Ab to the 2F5 epitope of HIV-1 may be proscribed by immune tolerance, a notion supported by impaired B-cell development in mice expressing the 2F5 VH and VL regions. However, there is a lack of quantitative and systemic assessment of polyreactivity among HIV bnAbs. In addition, it is unknown whether other classes of HIV-1 bnAbs and non-neutralizing a
APA, Harvard, Vancouver, ISO, and other styles
3

Lubow, Jay, Lisa M. Levoir, Duncan K. Ralph, et al. "Single B cell transcriptomics identifies multiple isotypes of broadly neutralizing antibodies against flaviviruses." PLOS Pathogens 19, no. 10 (2023): e1011722. http://dx.doi.org/10.1371/journal.ppat.1011722.

Full text
Abstract:
Sequential dengue virus (DENV) infections often generate neutralizing antibodies against all four DENV serotypes and sometimes, Zika virus. Characterizing cross-flavivirus broadly neutralizing antibody (bnAb) responses can inform countermeasures that avoid enhancement of infection associated with non-neutralizing antibodies. Here, we used single cell transcriptomics to mine the bnAb repertoire following repeated DENV infections. We identified several new bnAbs with comparable or superior breadth and potency to known bnAbs, and with distinct recognition determinants. Unlike all known flavivirus
APA, Harvard, Vancouver, ISO, and other styles
4

Sprenger, Kayla G., Joy E. Louveau, Pranav M. Murugan, and Arup K. Chakraborty. "Optimizing immunization protocols to elicit broadly neutralizing antibodies." Proceedings of the National Academy of Sciences 117, no. 33 (2020): 20077–87. http://dx.doi.org/10.1073/pnas.1919329117.

Full text
Abstract:
Natural infections and vaccination with a pathogen typically stimulate the production of potent antibodies specific for the pathogen through a Darwinian evolutionary process known as affinity maturation. Such antibodies provide protection against reinfection by the same strain of a pathogen. A highly mutable virus, like HIV or influenza, evades recognition by these strain-specific antibodies via the emergence of new mutant strains. A vaccine that elicits antibodies that can bind to many diverse strains of the virus—known as broadly neutralizing antibodies (bnAbs)—could protect against highly m
APA, Harvard, Vancouver, ISO, and other styles
5

Glazkova, D. V., E. V. Bogoslovskaya, G. A. Shipulin, and S. M. Yudin. "Broadly neutralizing antibodies for the treatment of HIV infection." HIV Infection and Immunosuppressive Disorders 13, no. 3 (2021): 81–95. http://dx.doi.org/10.22328/2077-9828-2021-13-3-81-95.

Full text
Abstract:
Antibodies with neutralizing activity against a wide range of human immunodeficiency virus 1 subtypes (known as broadly neutralizing antibodies — bNAb) are of great interest as a therapeutic agent for the treatment of HIV infection, because they are able to provide natural protection against most HIV-1 strains. The review discusses the mechanisms of formation of bNAbs, their classification by binding to conservative regions of the envelope protein, as well as their intrinsic features. Description of the most promising bNAbs and their combinations is presented.In the last section the results of
APA, Harvard, Vancouver, ISO, and other styles
6

Steichen, Jon M., Ying-Cing Lin, Colin Havenar-Daughton, et al. "A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses." Science 366, no. 6470 (2019): eaax4380. http://dx.doi.org/10.1126/science.aax4380.

Full text
Abstract:
Vaccine induction of broadly neutralizing antibodies (bnAbs) to HIV remains a major challenge. Germline-targeting immunogens hold promise for initiating the induction of certain bnAb classes; yet for most bnAbs, a strong dependence on antibody heavy chain complementarity-determining region 3 (HCDR3) is a major barrier. Exploiting ultradeep human antibody sequencing data, we identified a diverse set of potential antibody precursors for a bnAb with dominant HCDR3 contacts. We then developed HIV envelope trimer–based immunogens that primed responses from rare bnAb-precursor B cells in a mouse mod
APA, Harvard, Vancouver, ISO, and other styles
7

Shrader, Hannah, Sabrina Helmold Hait, Sarah Lovelace, et al. "Phenotypic analysis of HIV-1 resistance to CD4 binding site broadly-neutralizing antibodies." Journal of Immunology 210, no. 1_Supplement (2023): 223.08. http://dx.doi.org/10.4049/jimmunol.210.supp.223.08.

Full text
Abstract:
Abstract Broadly neutralizing antibodies (bNAbs) show strong immunotherapy potential by targeting conserved regions of the HIV-1 envelope. Single bNAb use in viremic individuals quickly results in the emergence of escape variants, likely originating from existing quasispecies. An ex vivo assay was developed to predict bNAb efficacy in viremic individuals. The development of a predictive bNAb efficacy model may assist with the planning of future clinical trials. The ex vivoassay used pre-infusion CD4 +T cells from participants enrolled in the VRC 607/ACTG A5378 phase I study of the CD4 binding
APA, Harvard, Vancouver, ISO, and other styles
8

Thavarajah, Jannifer Jasmin, Bo Langhoff Hønge, and Christian Morberg Wejse. "The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention." Viruses 16, no. 6 (2024): 911. http://dx.doi.org/10.3390/v16060911.

Full text
Abstract:
Background: Although antiretroviral therapy (ART) effectively halts disease progression in HIV infection, the complete eradication of the virus remains elusive. Additionally, challenges such as long-term ART toxicity, drug resistance, and the demanding regimen of daily and lifelong adherence required by ART highlight the imperative need for alternative therapeutic and preventative approaches. In recent years, broadly neutralizing antibodies (bNAbs) have emerged as promising candidates, offering potential for therapeutic, preventative, and possibly curative interventions against HIV infection.
APA, Harvard, Vancouver, ISO, and other styles
9

Kumar, Rajesh, Huma Qureshi, Suprit Deshpande, and Jayanta Bhattacharya. "Broadly neutralizing antibodies in HIV-1 treatment and prevention." Therapeutic Advances in Vaccines and Immunotherapy 6, no. 4 (2018): 61–68. http://dx.doi.org/10.1177/2515135518800689.

Full text
Abstract:
Antibodies that naturally develop in some individuals infected with human immunodeficiency virus 1 (HIV-1) and are capable of broadly neutralizing diverse strains of HIV-1 are useful for two applications: they can inform the rational design of vaccine immunogens, and they may be capable of preventing and treating HIV-1 infection when administered passively. A phase IIb study has been initiated with the experimental broadly neutralizing antibody (bnAb) VRC01, which has considerable breadth and potency (also referred to as a phase IIb HVTN 703/HPTN 081 and HVTN 704/HPTN 085 AMP efficacy trials)
APA, Harvard, Vancouver, ISO, and other styles
10

Xu, Ling, Amarendra Pegu, Ercole Rao, et al. "Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques." Science 358, no. 6359 (2017): 85–90. http://dx.doi.org/10.1126/science.aan8630.

Full text
Abstract:
The development of an effective AIDS vaccine has been challenging because of viral genetic diversity and the difficulty of generating broadly neutralizing antibodies (bnAbs). We engineered trispecific antibodies (Abs) that allow a single molecule to interact with three independent HIV-1 envelope determinants: the CD4 binding site, the membrane-proximal external region (MPER), and the V1V2 glycan site. Trispecific Abs exhibited higher potency and breadth than any previously described single bnAb, showed pharmacokinetics similar to those of human bnAbs, and conferred complete immunity against a
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Broadly neutralizing antibodies (bNAbs)"

1

Nemoz, Benjamin. "Exploration longitudinale à haut débit et en cellule unique du répertoire d'anticorps neutralisants à large spectre chez un neutraliseur d'élite du VIH-1." Electronic Thesis or Diss., Université Grenoble Alpes, 2024. http://www.theses.fr/2024GRALV012.

Full text
Abstract:
L'infection par le virus de l'immunodéficience humaine de type 1 (VIH-1) reste un problème majeur de santé publique à l'échelle mondiale, avec environ 37,7 millions de personnes vivant avec le virus et de nouvelles contaminations dépassant le million de cas par an. Des antirétroviraux efficaces permettent maintenant de traiter durablement les personnes infectées. Ces thérapies contribuent également à améliorer la prévention et à ralentir la progression de l'épidémie. Cependant, un vaccin reste nécessaire, en particulier pour contrôler l'épidémie dans les régions à faible revenu et les environn
APA, Harvard, Vancouver, ISO, and other styles
2

Derby, Nina Rafterman. "Designing immunogens to elicit broadly reactive neutralizing antibodies to the HIV envelope /." Thesis, Connect to this title online; UW restricted, 2007. http://hdl.handle.net/1773/9302.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Penn-Nicholson, Adam Garth. "Characterization and evaluation of approaches to elicit Broadly Reactive Neutralizing Antibodies against HIV-1." Case Western Reserve University School of Graduate Studies / OhioLINK, 2008. http://rave.ohiolink.edu/etdc/view?acc_num=case1205433621.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Suphaphiphat, Karunasinee. "Anti-viral immune response in the semen of cynomolgus macaques and inhibition of cell to cell transmission by broadly neutralizing antibodies in an SIV/SHIV model of infection SHIV162P3 transmission by semen 1 leukocytes is efficiently 2 inhibited by broadly neutralizing antibodies." Thesis, Université Paris-Saclay (ComUE), 2019. http://www.theses.fr/2019SACLS599.

Full text
Abstract:
La transmission sexuelle du VIH-1 se fait principalement via du sperme infecté contaminé, contenant à la fois des virions libres et des leucocytes infectés. Les facteurs présents dans le liquide séminal peuvent aussi moduler l’infectivité du sperme et la réponse immunitaire de l’hôte. Ainsi, le macaque infecté par le virus de l’immunodéficience simienne (VIS) sera utilisé comme modèle expérimental afin d’étudier l’infectivité des cellules séminales, les réponses immunitaires anti-virales et évaluer l’effet inhibiteur d’anticorps neutralisant à large spectre (bNAbs) sur la transmission du virus
APA, Harvard, Vancouver, ISO, and other styles
5

Corti, Davide. "Analysis of the human B cell memory repertoire against infectious pathogens and isolation of broadly neutralizing human monoclonal antibodies /." Bern : [s.n.], 2008. http://www.ub.unibe.ch/content/bibliotheken_sammlungen/sondersammlungen/dissen_bestellformular/index_ger.html.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Yuan, Tingting, and 袁婷婷. "Identification of intermediate antibodies of broadly neutralizing HIV-1 human monoclonal antibody b12 and characterization of variable loops of HIV-1 envelop glycoprotein." Thesis, The University of Hong Kong (Pokfulam, Hong Kong), 2013. http://hdl.handle.net/10722/196445.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Gardner, Matthew Ryan. "Targeting the CD4- and Coreceptor-Binding Sites of the HIV-1 Envelope Glycoprotein." Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11644.

Full text
Abstract:
The HIV-1 envelope glycoprotein, Env, facilitates the translocation of the viral capsid across the cellular membrane. Env is a trimer of hetero-dimers composed of a gp120 subunit and gp41 transmembrane protein. The gp120 subunit binds the primary receptor, CD4, leading to conformational changes of Env that then promote binding to the coreceptor, principally CCR5 or CXCR4. As the sole protein on the surface of the virion, Env is under continuous pressure from the host's antibody response. Two classes of antibodies target the highly conserved receptor-binding sites of gp120: CD4-binding site
APA, Harvard, Vancouver, ISO, and other styles
8

Cheng, Yuxing. "Elicitation of antibody responses against the HIV-1 gp41 Membrane Proximal External Region (MPER)." Thesis, Harvard University, 2014. http://dissertations.umi.com/gsas.harvard:11427.

Full text
Abstract:
An effective vaccine to protect against HIV-1/AIDS remains elusive due to the extensive mechanisms employed by the HIV-1 virus to evade immune attack. Highly potent broadly neutralizing antibodies isolated from chronically infected individuals, however, show that such relevant antibodies can be naturally produced, implying that their elicitation through vaccination is a realistic possibility. These broadly neutralizing antibodies target different regions on the trimeric spikes formed by three protomers of the envelope (Env) protein. Each Env protein is comprised of the gp120 surface subunit in
APA, Harvard, Vancouver, ISO, and other styles
9

Miles, Brodie, Shannon M. Miller, and Elizabeth Connick. "CD4 T Follicular Helper and Regulatory Cell Dynamics and Function in HIV Infection." FRONTIERS MEDIA SA, 2016. http://hdl.handle.net/10150/622733.

Full text
Abstract:
T follicular helper cells (T-FH) are a specialized subset of CD4 T cells that reside in B cell follicles and promote B cell maturation into plasma cells and long-lived memory B cells. During chronic infection prior to the development of AIDS, HIV-1 (HIV) replication is largely concentrated in T-FH. Paradoxically, T-FH numbers are increased in early and midstages of disease, thereby promoting HIV replication and disease progression. Despite increased T-FH numbers, numerous defects in humoral immunity are detected in HIV-infected individuals, including dysregulation of B cell maturation, impaire
APA, Harvard, Vancouver, ISO, and other styles
10

Hashem, Anwar. "Targeting the Highly Conserved Sequences in Influenza A Virus." Thèse, Université d'Ottawa / University of Ottawa, 2013. http://hdl.handle.net/10393/24058.

Full text
Abstract:
All challenges associated with influenza A viruses including antigenic variation in hemagglutinin (HA) and neuraminidase (NA), the evolving drug resistance and the drawbacks of current vaccines hinder our ability to control this constant threat. Furthermore, gene reassortment as well as the direct transmission of highly pathogenic avian viruses to humans can result in an occasional emergence of novel influenza strains with devastating pandemic potential. Therefore, it is crucial to investigate alternative approaches to better control these viruses and to develop new prophylactic and treatment
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Broadly neutralizing antibodies (bNAbs)"

1

Cox, Josephine H., Stuart Z. Shapiro, Liza Dawson, Cynthia Geppert, Andrew M. Siegel, and M. Patricia D’Souza. Vaccines for The Prevention and Treatment of HIV Infection. Edited by Mary Ann Cohen, Jack M. Gorman, Jeffrey M. Jacobson, Paul Volberding, and Scott Letendre. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199392742.003.0032.

Full text
Abstract:
While the HIV/AIDS pandemic continues, the overall incidence of HIV infections has fallen through use of antiretroviral therapy (ART) and multiple prevention modalities. To achieve a durable end to the pandemic and avoid the requirement for daily antiretroviral medication over a lifetime, a safe and effective prophylactic vaccine remains essential. This chapter reviews current advances in prophylactic and therapeutic HIV-1 vaccine strategies and the challenges that lie ahead. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs) from infected individuals, the discovery
APA, Harvard, Vancouver, ISO, and other styles
2

Schommers, Philipp, Harry Gristick, Marit J. Van Gils, and Kshitij Wagh, eds. Novel Concepts in Using Broadly Neutralizing Antibodies for HIV-1 Treatment and Prevention. Frontiers Media SA, 2022. http://dx.doi.org/10.3389/978-2-88974-305-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Broadly neutralizing antibodies (bNAbs)"

1

Wu, Xueling. "HIV Broadly Neutralizing Antibodies: VRC01 and Beyond." In HIV Vaccines and Cure. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_3.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Zhou, Tongqing, and Kai Xu. "Structural Features of Broadly Neutralizing Antibodies and Rational Design of Vaccine." In HIV Vaccines and Cure. Springer Singapore, 2018. http://dx.doi.org/10.1007/978-981-13-0484-2_4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Pauthner, Matthias G., and Lars Hangartner. "Broadly Neutralizing Antibodies to Highly Antigenically Variable Viruses as Templates for Vaccine Design." In Current Topics in Microbiology and Immunology. Springer International Publishing, 2020. http://dx.doi.org/10.1007/82_2020_221.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Zhang, Mei-Yun, and Dimiter S. Dimitrov. "Sequential Antigen Panning for Selection of Broadly Cross-Reactive HIV-1-Neutralizing Human Monoclonal Antibodies." In Methods in Molecular Biology. Humana Press, 2009. http://dx.doi.org/10.1007/978-1-60327-302-2_11.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Van Regenmortel, Marc H. V. "Why Does the Molecular Structure of Broadly Neutralizing Monoclonal Antibodies Isolated from Individuals Infected with HIV-1 Not Inform the Rational Design of an HIV-1 Vaccine?" In HIV/AIDS: Immunochemistry, Reductionism and Vaccine Design. Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-32459-9_19.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Morris, L., and T. A. Moody. "Broadly Neutralizing Antibodies." In Human Vaccines. Elsevier, 2017. http://dx.doi.org/10.1016/b978-0-12-802302-0.00012-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Mohamed, Yehia. "The Future of HIV Vaccine Development, Learned Lessons from COVID-19 Pandemic." In New Topics in Vaccine Development [Working Title]. IntechOpen, 2024. http://dx.doi.org/10.5772/intechopen.114355.

Full text
Abstract:
With nearly 13 million new HIV infections in 2022, it is imperative that as many preventive options be available to those most at risk. Without doubt, an effective vaccine would be a game changer, and despite the disappointments and challenges, the development of an effective HIV vaccine should remain a priority. The past few years have been tough for HIV vaccine research, with several high-profile trials being stopped early and others having negative results. With every setback, however, there are lessons to be learned. Neutralizing antibodies (bnAbs), either by giving infusions of bnAbs or b
APA, Harvard, Vancouver, ISO, and other styles
8

Ni, Fengyun, and Qinghua Wang. "Stem-specific Broadly Neutralizing Antibodies of Influenza Virus Hemagglutinin." In Influenza: Current Research. Caister Academic Press, 2016. http://dx.doi.org/10.21775/9781910190432.01.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Haynes, Barton F., Kevin O. Saunders, Garnett Kelsoe, John R. Mascola, and Gary J. Nabel. "The Cellular and Molecular Biology of HIV-1 Broadly Neutralizing Antibodies." In Molecular Biology of B Cells. Elsevier, 2015. http://dx.doi.org/10.1016/b978-0-12-397933-9.00024-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Mallard, Bonnie, Mehdi Emam, Shannon Cartwright, et al. "Advances in understanding immune response in dairy cattle." In Improving dairy herd health Improving. Burleigh Dodds Science Publishing, 2021. http://dx.doi.org/10.19103/as.2020.0086.06.

Full text
Abstract:
From the beginning, cattle have made important contributions to the field of immunology, including the development of the first Mycobacterium bovis BCG vaccine for human tuberculosis in 1921. In 1981 the first report of a biosynthesized polypeptide vaccine against Foot and Mouth Disease Virus (FMDV) using the VP3 protein expressed in Escherichia coli (E. coli) was made for cattle. Cattle also possess a substantial proportion of T cells expressing the γδ T-cell receptor which helped to elucidate the role of these unique cells in host defence. More recently, it was discovered that cattle produce
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Broadly neutralizing antibodies (bNAbs)"

1

Morton, Scott P., and Joshua L. Phillips. "pH Dependent Binding Energies of Broadly Neutralizing Antibodies." In 2021 IEEE International Conference on Bioinformatics and Biomedicine (BIBM). IEEE, 2021. http://dx.doi.org/10.1109/bibm52615.2021.9669511.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Solodkov, P. P., T. N. Belovezhets, A. N. Chikaev, et al. "SINGLE DOMAIN LLAMA ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS." In X Международная конференция молодых ученых: биоинформатиков, биотехнологов, биофизиков, вирусологов и молекулярных биологов — 2023. Novosibirsk State University, 2023. http://dx.doi.org/10.25205/978-5-4437-1526-1-127.

Full text
Abstract:
The late stage of the COVID-19 pandemic is marked by the appearance of mutant variants of SARS-CoV-2 that can escape the immunity against the Wuhan virus. In this work, we report on the development of a panel of antiviral agents — single-domain antibodies that recognize independent epitopes of the SARS-CoV-2 S protein. Four antibodies from this panel neutralize a wide range of virus variants, including the most common ones at present: XBB.1.5 and XBB.1.16.
APA, Harvard, Vancouver, ISO, and other styles
3

Desyukevich, P. Y., P. P. Solodkov, T. N. Belovezhets, and A. N. Chikaev. "RECOMBINANT VHH-BASED MULTIVALENT ANTIBODIES BROADLY NEUTRALIZING SARS-COV-2 VARIANTS." In XI МЕЖДУНАРОДНАЯ КОНФЕРЕНЦИЯ МОЛОДЫХ УЧЕНЫХ: БИОИНФОРМАТИКОВ, БИОТЕХНОЛОГОВ, БИОФИЗИКОВ, ВИРУСОЛОГОВ, МОЛЕКУЛЯРНЫХ БИОЛОГОВ И СПЕЦИАЛИСТОВ ФУНДАМЕНТАЛЬНОЙ МЕДИЦИНЫ. IPC NSU, 2024. https://doi.org/10.25205/978-5-4437-1691-6-65.

Full text
Abstract:
The high genetic variability of SARS-CoV-2 leads to the emergence of new escape variants that are resistant to most currently available therapeutic monoclonal antibodies. In this study, we developed a panel of novel bispecific antibodies derived from llama nanobodies targeting three distinct epitopes in the SARS-CoV-2 spike RBD. These newly derived antibodies were shown to potently neutralize a wide range of SARS-CoV-2 variants including JN.1 and KP.2 Omicron sublineages, as well as genetically related SARSCoV-1 sarbecovirus.
APA, Harvard, Vancouver, ISO, and other styles
4

Flyak, Andrew I., Stormy Ruiz, Michelle Colbert, et al. "Abstract B109: Broadly neutralizing antibodies against HCV use a CDRH3 disulfide motif to recognize an E2 glycoprotein site that can be targeted for vaccine design." In Abstracts: Fourth CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival; September 30 - October 3, 2018; New York, NY. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/2326-6074.cricimteatiaacr18-b109.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Broadly neutralizing antibodies (bNAbs)' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography